Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The broker retains its hold rating, warning that overall portfolio growth may stall even as the oral weight-loss pill gains traction Jefferies has trimmed its price target on Novo Nordisk (NYSE:NVO) , the Danish pharmaceutical giant, to DKK270 from DKK275, maintaining a 'hold' rating ahead of first-quarter results. The change came as the broker flagged mounting uncertainty around GLP-1 pricing, oral Wegovy's launch trajectory and the risk that the new pill cannibalises rather than grows the overall franchise. GLP-1 refers to glucagon-like peptide-1, the class of drugs that underpins Novo's Ozempic and Wegovy treatments for diabetes and obesity, respectively, and which has driven the company's extraordinary growth in recent years. The central concern in the Jefferies note is that higher oral Wegovy prescription estimates for 2026, now forecast to generate around 12 billion Danish krone in first-year sales, are being largely offset by cuts to the injectable portfolio following
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Form Health Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 [Yahoo! Finance]Yahoo! Finance
- Greater weight loss promised by higher-dose Wegovy shot, now approved by FDA [FOX News]FOX News
- iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors [TheStreet.com]TheStreet.com
- iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors [Yahoo! Finance]Yahoo! Finance
- As demand for GLP-1 pills and shots surges, healthy habits are still key [Los Angeles Times (CA)]Los Angeles Times
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/23/26 - Form 6-K
- 3/20/26 - Form 6-K
- 3/17/26 - Form 6-K
- NVO's page on the SEC website